1 Introduction Advances in multimodal breast cancer therapy have significantly improved survival, resulting in a growing population of long-term survivors and an increased incidence of second primary malignancies (1, 2). Metachronous PDAC after breast cancer is a rare but serious occurrence, typically linked to hereditary predisposition syndromes involving pathogenic variants in homologous recombination repair (HRR) genes such as BRCA2, PALB2, and ATM (3–5).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Hui
Contact Hui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack